ADP-ribosyl Cyclase and Cyclic ADP-ribose Hydrolase Act as a Redox Sensor

A PRIMARY ROLE FOR CYCLIC ADP-RIBOSE IN HYPOXIC PULMONARY VASOCONSTRICTION*

Heather L. WilsonDagger §, Michelle Dipp, Justyn M. ThomasDagger , Chetan LadDagger , Antony GalioneDagger ||, and A. Mark EvansDagger **

From the Dagger  University Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT and the  University Laboratory of Physiology, University of Oxford, Parks Road, Oxford, OX1 3PT, United Kingdom

Received for publication, June 5, 2000, and in revised form, December 13, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hypoxic pulmonary vasoconstriction is unique to pulmonary arteries and serves to match lung perfusion to ventilation. However, in disease states this process can promote hypoxic pulmonary hypertension. Hypoxic pulmonary vasoconstriction is associated with increased NADH levels in pulmonary artery smooth muscle and with intracellular Ca2+ release from ryanodine-sensitive stores. Because cyclic ADP-ribose (cADPR) regulates ryanodine receptors and is synthesized from beta -NAD+, we investigated the regulation by beta -NADH of cADPR synthesis and metabolism and the role of cADPR in hypoxic pulmonary vasoconstriction. Significantly higher rates of cADPR synthesis occurred in smooth muscle homogenates of pulmonary arteries, compared with homogenates of systemic arteries. When the beta -NAD+:beta -NADH ratio was reduced, the net amount of cADPR accumulated increased. This was due, at least in part, to the inhibition of cADPR hydrolase by beta -NADH. Furthermore, hypoxia induced a 10-fold increase in cADPR levels in pulmonary artery smooth muscle, and a membrane-permeant cADPR antagonist, 8-bromo-cADPR, abolished hypoxic pulmonary vasoconstriction in pulmonary artery rings. We propose that the cellular redox state may be coupled via an increase in beta -NADH levels to enhanced cADPR synthesis, activation of ryanodine receptors, and sarcoplasmic reticulum Ca2+ release. This redox-sensing pathway may offer new therapeutic targets for hypoxic pulmonary hypertension.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Since it was first described over 50 years ago, hypoxic pulmonary vasoconstriction (HPV)1 has been recognized as the critical and distinguishing characteristic of the blood vessels of the lung (1). Thus, in marked contrast to systemic arteries, which dilate in response to hypoxia, pulmonary arteries constrict. Physiologically, HPV contributes to the matching of lung perfusion and ventilation. However, when alveolar hypoxia is global, as it is in disease states such as cystic fibrosis, emphysema, and mountain sickness, it results in pulmonary hypertension, which can ultimately lead to right heart failure. Unfortunately, the precise mechanisms that underpin HPV remain to be identified, and current therapies for hypoxic pulmonary hypertension are poor.

Certain key characteristics of HPV have been described. In isolated pulmonary arteries, HPV is biphasic. An initial transient constriction (phase 1) is followed by a slowly developing, sustained phase of constriction (phase 2). It is widely thought that the first phase of constriction is initiated by a reduction in membrane K+ conductance in pulmonary artery smooth muscle cells (2-4), membrane depolarization, and Ca2+ influx through voltage-gated Ca2+ channels (5-8). Phase 2 of the constriction is tonic and may depend on the release of a vasoconstrictor from the endothelium, which sensitizes the contractile apparatus to Ca2+ (9, 10).

Our recent findings (11) do not support the above hypothesis. They suggest that hypoxia may, by activating a mechanism intrinsic to pulmonary artery smooth muscle cells, induce intracellular Ca2+ release from ryanodine-sensitive stores in the absence of transmembrane Ca2+ influx. This proposal is also supported by the findings of others (12, 13). Also, we have established that the hypoxia-induced SR Ca2+ release initiates and maintains acute HPV (11). Details of the signal transduction pathway remain to be clarified. One possibility is that the beta -NAD+ metabolite cyclic ADP-ribose (cADPR; Refs. 14-16), a messenger that regulates SR Ca2+ release via ryanodine receptors (RyRs) in a variety of cell types (17-19), plays a role in this process.

We have investigated the role of the beta -NAD+:beta -NADH ratio in regulating cADPR synthesis in pulmonary artery smooth muscle because of the fact that (a) the cellular redox couple beta -NAD+ is the recognized substrate for cADPR synthesis; (b) the redox state of O2-sensing cells is uniquely sensitive to changes in the level of O2 (20); (c) hypoxia has been shown to reduce the NAD(P): NAD(P)H ratio in all O2-sensing cells studied to date, including carotid body type I cells (20, 21), airway neuroepithelial cells (22), and pulmonary artery smooth muscle cells (3, 23); and (d) the hypoxia-induced fall in the NAD(P):NAD(P)H ratio in carotid body type I cells occurs with a time course similar to the hypoxia-induced increase in intracellular Ca2+ (21).

We report that the enzyme activities for cADPR synthesis and metabolism are particularly high in pulmonary artery smooth muscle, as opposed to systemic artery smooth muscle. We show that hypoxia, by increasing beta -NADH levels, inhibits cADPR hydrolase, which in turn promotes an increase in cADPR levels in pulmonary artery smooth muscle. Furthermore, we show that a membrane-permeant cADPR antagonist, 8-bromo-cADPR, abolishes the second, sustained phase of HPV. The role of ADP-ribosyl cyclase and cADPR hydrolase as a redox sensor is discussed.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Male New Zealand White rabbits (1-2 Kg) were stunned and killed by cervical dislocation. Heart and lungs were removed and placed in PSS A (124 mM NaCl, 5 mM KCl, 15 mM NaH2CO3, 1.8 mM CaCl2, 1 mM MgCl2, 0.5 mM NaH2PO4, 0.5 mM KH2PO4, 15 mM HEPES, and 10 mM glucose, pH 7.4, 95% air, 5% CO2). Pulmonary arteries, mesenteric arteries, and aorta were dissected free and cleaned.

Homogenates-- The endothelium was removed by rubbing the luminal surface with a cotton bud, and 2-mm artery strips were cut and placed in 1 ml of Ca2+-free sucrose-HEPES buffer (250 mM and 20 mM, respectively, pH 7.2). The preparation was homogenized by 2× 5-s bursts using an ultra-turrex homogenizer; 2× 5 strokes using a glass Dounce homogenizer (pestle D). Homogenates were centrifuged for 12 min at 2,000 × g and 4 °C to remove debris and nuclei. The supernatant was stored at -70 °C. Production of cADPR from 2.5 mM beta -NAD+ and metabolism of 5-10 µM cADPR, respectively, was assessed in 10-50-µl samples of smooth muscle homogenate at 37 °C. Test samples (5 µl) were assayed for cADPR using a Ca2+ release bioassay (see below).

Smooth Muscle Cell Isolation-- Smooth muscle cells were isolated as previously described (24). Prior to enzyme assays only, cells were washed in sucrose-HEPES buffer, centrifuged at 1,000 × g for 5 min at 4 °C, resuspended, and washed once in (a) phosphate-buffered saline (120 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer salts; pH 7.4), (b) phosphate-buffered saline plus 1 mM EGTA, or (c) 100-300 µl of sucrose-HEPES buffer. Buffers contained protease inhibitors: 25 µg/ml leupeptin, 20 µg/ml aprotinin, and 100 µg/ml soy bean trypsin inhibitor. Cells were permeabilized with saponin (50 µg/ml) for 30 min at 24 °C. Permeabilization was confirmed by trypan blue exclusion.

Sea Urchin Egg Homogenate Ca2+ Release Bioassay-- Homogenates were prepared and "calcium-loaded" in an intracellular medium (250 mM potassium gluconate, 250 mM N-methyl-glucamine, 20 mM HEPES, 1 mM MgCl2, 1 mM ATP, 10 units/ml creatine phosphokinase, and 10 mM phosphocreatine, pH 7.2) as described previously (25, 26). Intracellular medium also contained protease inhibitors (25 mg/ml leupeptin, 10 mg/ml aprotinin, and 100 µg/ml soy bean trypsin inhibitor) and mitochondrial inhibitors (1 µg/ml oligomycin, 1 µg/ml antimycin, and 1 mM sodium azide). Fluo-3 (3 mM) was used as a Ca2+ indicator (excitation = 490 nm, emission = 535 nm). Changes in free Ca2+ induced by 5-µl test samples were measured at 17 °C using 500 µl of sea urchin egg homogenate in a PerkinElmer LS-50B fluorimeter. cADPR was identified by homologous desensitization of ryanodine receptors (27) and quantified by interpolation with standard concentration-response curves (28).

Continuous ADP-ribosyl Cyclase Assay-- The substrate was NGD+ (250 µM). Autofluorescence of the product, cyclic GDP-ribose, was measured with excitation and emission wavelengths of 300 and 410 nm, respectively (29). Reaction mixture (500 µl) contained test homogenate diluted 1 in 10 with sucrose-HEPES buffer.

Differential Centrifugation-- Homogenates were separated by differential centrifugation: P1, nuclear and whole cell debris (1,000 × g); P2, plasma membrane (8,000 × g); P3, microsomal membranes (SR and mitochondria; 100,000 × g); S3, cytosolic fraction (30).

Protein Concentration-- Estimated using the BCA protein assay (Sigma).

Electrophysiology-- Membrane potential recordings in isolated pulmonary artery smooth muscle cells were made at 22 °C, under current clamp (I = 0) and using the whole cell configuration of the patch clamp technique, as described previously (31). Data were acquired and analyzed using an Axopatch 200B amplifier and pCLAMP 6.0 data acquisition and analysis software (Axon Instruments). The pipette solution was 140 mM KCl, and 10 mM HEPES, pH 7.4. The bath solution was 130 mM NaCl, 5 mM KCl, 2 mM glucose, 10 mM HEPES, 1.7 mM CaCl2, and 2 mM MgCl2, pH 7.45.

Small Vessel Myography-- Vessels were always obtained from the same anatomical position within the lung, i.e. third order branches of the pulmonary arterial tree (inner diameter, 300-400 µm). Vessels (2-3 mm in length) were mounted on to the jaws of an automated myograph (AM10, Cambustion Biological, Cambridge, UK) using 50-µm tungsten wire. Initial tension was set to be equivalent to typical pulmonary arterial pressure. The detailed technique, protocol, and theory have been described previously (32). Vessels were bathed in PSS B (constituents as for PSS A, but with 24 mM NaHCO3 and no HEPES) at 37 ± 1 °C and in a bath volume of 4 ml. The solution was bubbled with 75% N2, 20% O2, 5% CO2 to maintain a pH of 7.4.

All arteries were first subjected to four exposures of high K+ (75 mM) to test their responsiveness and stability. Resting tension was taken to be zero. The bath chambers containing PSS B were individually sealed and bubbled with either normoxic (154-160 Torr; 75% N2, 20% O2, 5% CO2) or hypoxic (16-21 Torr; 93% N2, 2% O2, 5% CO2) gas, supplied via a gas-mixing flowmeter (Cameron Instruments Ltd., Port Aransas, TX). The desired PaO2 was confirmed using an Oxel O2 electrode and meter (World Precision Instruments). All drugs were applied to the bath directly. All solutions were warmed to 37 °C before adding them to the bath.

When required, the endothelium of the arteries was removed by rubbing the inner surface with braided silk surgical thread. Removal of the endothelium was assessed by the ability of 100 µM acetylcholine to relax constrictions induced by 1 µM prostaglandin F2alpha .

Extraction and Measurement of Endogenous cADPR-- Second and third order branches of the pulmonary artery were placed in chambers containing PSS B that were individually sealed and bubbled with either normoxic (154-160 Torr; 75% N2, 20% O2, 5% CO2) or hypoxic (16-21 Torr; 93% N2, 2% O2, 5% CO2) gas as described above (see small vessel myography). Vessels were quickly removed from the experimental chambers and snap frozen in liquid nitrogen. Acid extraction of nucleotides/cADPR was carried out using a variation of a method described previously (33). Briefly, the frozen tissue was powdered, added to ice-cold 3 M perchloric acid (1:1 w/v) and sonicated for 20 s. After sonication the samples were left in an ice-salt bath (-5 °C) for 30 min to allow for extraction of nucleotides. Precipitated protein was then removed by centrifugation (15,000 × g for 10 min). The supernatant was neutralized by the addition of 2 M KHCO3. The potassium perchlorate precipitate was removed by centrifugation at 15,000 × g for 10 min. To remove contaminating nucleotides that weakly interfere with [32P]cADPR binding, the neutralized acid extracts were treated with NADase (0.25 unit/ml), nucleotide pyrophosphatase (1.75 units/ml), alkaline phosphatase (50 units/ml), and apyrase (5 units/ml) for 4 h, as previously described (15). The concentration of cADPR in acid extracts was assessed by comparing inhibitory effects on the [32P]cADPR binding assay, with a standard curve constructed using authentic cADPR. As a control each sample was heat treated at 85 °C for 45 min, to hydrolyze cADPR to ADPR. The inhibitory effect on [32P]cADPR binding of all samples was abolished by heat treatment. The recovery of cADPR, monitored by recovery of [32P]cADPR added prior to acid extraction, was 69.9 ± 5.2% (n = 3). Correction was introduced for recovery of cADPR.

[32P] cADPR Binding Assay-- Enzymatic synthesis of [32P]cADPR and determination of specific [32P]cADPR binding to sea urchin egg homogenate were performed using methods described previously (35, 36).

Materials-- Lytechinus pictus sea urchins were from Marinus Inc. (Long Beach, CA). Chemicals were from Sigma, except Fluo-3, which was from Molecular Probes, and [32P]beta -NAD+, which was from Amersham Pharmacia Biotech.

Statistical Significance-- Statistical significance was assessed by analysis of variance and assumed if p < 0.05. Data were expressed as the means ± S.E. for n animals tested unless stated. In biochemical assays each sample was assayed in triplicate.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Synthesis and Degradation of cADPR Occurs in Pulmonary Artery Smooth Muscle Homogenates-- Fig. 1A illustrates the time course of cADPR synthesis from 2.5 mM beta -NAD+ in smooth muscle homogenates from third order branches of the pulmonary arterial tree, as determined by the sea urchin homogenate bioassay. The synthesis was complete after 45 min, when 18 ± 1.7 nmol of cADPR were synthesized per mg of protein (n = 5 animals). Homogenates showed a similar time-dependent hydrolysis of 5 µM cADPR, assessed by bioassay. This was complete at 60 min, when 10 ± 0.6 nmol of cADPR had been metabolized per mg of protein (n = 4 animals; Fig. 1B). The inset in Fig. 1A shows that 250 µM NGD+, an alternative substrate for ADP-ribosyl cyclase, yielded a fluorecent cyclic product (cyclic GDP-ribose) when NGD+ was added to smooth muscle homogenates of third order branches of the pulmonary artery. When NGD+ was excluded, no change in fluorescence was observed with time (trace 1). Upon addition of NGD+ a significant increase in the fluorescence was observed with time (trace 2). The increase in fluorescence was clearly dependent on cyclic GDP-ribose formation and therefore ADP-ribosyl cyclase, because it was inhibited by the ADP-ribosyl cyclase antagonist nicotinamide (10 mM; trace 3; see also Refs. 25 and 26).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Time course for the synthesis and degradation of cADPR in smooth muscle homogenates of third order branches of the pulmonary artery. A, the production of cADPR from 2.5 mM beta -NAD+. The inset shows the rate of change in fluorescence resulting from the production of cyclic GDP-ribose in the absence of substrate (trace 1), in the presence of 250 µM NGD+ (trace 2), and in the presence of 250 µM NGD+ and 10 mM nicotinamide (trace 3); the excitation wavelength was 300 nm, and the emission wavelength was 410 nm. B, rate of degradation of 5 µM cADPR by smooth muscle homogenates. The points and error bars represent the means ± S.E. for >= 5 animals. All incubations were carried out at 37 °C and in triplicate. Delta RFU, change in relative fluorescence units.

cADPR Synthesis Occurs at an Intracellular Site-- Because both ecto-enzymes and intracellular enzymes with ADP-ribosyl cyclase activities have been reported (37), it was important to show whether or not cADPR could be synthesized intracellularly, because this would probably be more relevant to an intracellular signaling role. To achieve this we studied the enzyme activities in the cellular fractions obtained from differential centrifugation of smooth muscle homogenates from third order branches of the pulmonary artery. Fig. 2A shows that the synthesis of cADPR was detected in each of the membrane fractions. However, the rate of synthesis was highest in the P3 (microsomal; SR and mitochondria) fraction at 9.5 ± 1.1 nmol/mg of protein/h (n = 3 animals), compared with 2.5 ± 0.7 nmol/mg of protein/h (n = 3 animals) in the P2 fraction (plasma membrane), 0.25 ± 0.01 nmol/mg of protein/h (n = 3 animals) in the P1 fraction (nuclear and whole cell debris), and 0.01 ± 0.1 nmol/mg of protein/h (n = 3 animals) in the S3 fraction (cytosolic). Fig. 2B shows a similar distribution for cADPR metabolism. The rate of metabolism was highest in the P3 (microsomal; SR and mitochondria) fraction at 2.6 ± 0.3 nmol/mg of protein/h (n = 3 animals), compared with 0.92 ± 0.02 nmol/mg of protein/h (n = 3 animals) in the P2 fraction (plasma membrane). In contrast, the hydrolase activity in the P1 fraction (nuclear and whole cell debris; n = 3 animals) and in the S3 fraction (cytosolic; n = 3 animals), respectively, was undetectable. Fig. 2C shows the distribution of a 5' nucleotidase reaction used to estimate the relative level of plasma membrane associated protein in all four fractions. The highest level of 5' nucleotidase activity was 129 ± 19 units/liter for the P2 (plasma membrane) fraction (n = 3 animals), compared with 86 ± 5.5 U/liter (n = 3 animals) for the P3 (microsomal) fraction and 56 ± 2.2 U/liter (n = 3 animals) for the P1 (nuclear and whole cell debris) fraction. Clearly, the P2 fraction had a much lower level of ADP-ribosyl cyclase and cADPR hydrolase activity than the P3 pellet. The ADP-ribosyl cyclase and cADPR hydrolase activity did not, therefore, follow the plasma membrane contamination.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   The enzymes for the synthesis of cADPR are located at an intracellular site. A, the rate of cADPR synthesis (nmol/mg protein/h) in the P1 (nuclear and whole cell debris), P2 (plasma membrane), P3 (microsomal), and S3 (cytosolic) fractions of smooth muscle homogenates of third order branches of the pulmonary artery; each fraction was separated by differential centrifugation. B, the rate of cADPR metabolism (nmol/mg protein/h) in each fraction. C, the relative plasma membrane contamination as indicated by the 5' nucleotidase (5'ND) activity (units of activity/liter) in P1, P2, P3, and S3 fractions. D, production of cADPR by whole (open bars) and saponin permeabilized (black bars) pulmonary artery smooth muscle cells acutely isolated from the extrapulmonary artery. The inset shows a typical image of an isolated pulmonary artery smooth muscle cell in sucrose-HEPES buffer. All incubations were carried out at 37 °C and in triplicate. Bars represent the means ± S.E. for >=  3 animals. *, significance of p < 0.05.

Fig. 2D shows cADPR synthesis using whole and saponin (50 µg/ml) permeabilized pulmonary artery smooth muscle cells isolated from the large extrapulmonary artery. A significantly greater level of synthesis was detected in permeabilized smooth muscle cells. Thus, after a 120-min incubation with 2.5 mM beta -NAD+ the production of cADPR measured 0.51 ± 0.07 nmol/mg protein (n = 3 animals) in whole cells and 1.5 ± 0.4 nmol/mg protein (n = 3 animals) in paired and time-matched permeabilized cells (Fig. 2D). A clear separation in the level of cADPR synthesis in whole versus permeabilized pulmonary artery smooth muscle cells, respectively, was not, however, observed at the 60-min time point. This apparent nonlinearity may be a product of (a) the sensitivity of the Ca2+ release bioassay to cADPR and (b) the time required for sufficient quantities of the newly synthesized cADPR to accumulate in the samples tested. Note that the saponin concentration used was found to have no effect on the Ca2+ release bio-assay (see methods). Fig. 2D (inset) shows a picture of an isolated and saponin permeabilized pulmonary artery smooth muscle cell in suspension.

ADP-ribosyl Cyclase and Hydrolase Activity Is Differentially Distributed in Pulmonary and Systemic Artery Smooth Muscle-- Fig. 3A compares the level of cADPR synthesis by homogenates of pulmonary and systemic arterial smooth muscle following a 1-h incubation with 2.5 mM beta -NAD+. The quantity of cADPR produced was high in smooth muscle homogenates from all sections of the pulmonary arterial tree, whereas no significant production could be detected in homogenates of either the aorta or mesenteric artery. Moreover, the level of cADPR synthesis was inversely related to pulmonary artery diameter, measuring 1.0 ± 0.4 nmol/mg of protein/h (n = 4 animals) in homogenates of the large conduit or extrapulmonary artery, 9.1 ± 2.8 nmol/mg protein/h (n = 5 animals) in the second order branches of the pulmonary artery (intrapulmonary artery) and 18 ± 1.7 nmol/mg protein/h (n = 6 animals) in the third order branches. Fig. 3B shows that the rate of hydrolysis of 5 µM cADPR in the same series of artery homogenates followed a similar pattern, measuring 11 ± 1.5 nmol/mg protein/h (n = 4 animals) in smooth muscle homogenates of the third order branches, 5.7 ± 2.3 nmol/mg protein/h (n = 5 animals) in second order branches, and 2.3 ± 2.2 nmol/mg protein/h (n = 4 animals) in homogenates of the extrapulmonary artery. In contrast to cADPR synthesis, a small amount of cADPR hydrolysis was detected in homogenates of both the aorta (0.6 ± 0.3 nmol/mg protein/h; n = 3 animals) and the near-resistance sized mesenteric arteries (200-1000 µm external diameter; 0.4 ± 0.2 nmol/mg protein/h, n = 3 animals). These findings suggest that ADP-ribosyl cyclase and cADPR may play an important role in the regulation of pulmonary artery smooth muscle cell function.



View larger version (8K):
[in this window]
[in a new window]
 
Fig. 3.   Enzyme activities for cADPR synthesis and metabolism in rabbit pulmonary and systemic arteries. A, the rate of cADPR production from 2.5 mM beta -NAD+ in homogenates of smooth muscle from third order branches of the pulmonary artery (RP), second order branches of the pulmonary artery (IP), and the main or extrapulmonary artery (EP). These are compared with the rate of cADPR production in the thoracic aorta, third order branches of the mesenteric artery (RM) and the main conduit mesenteric artery (CM). B, rate of degradation of 5 µM cADPR in smooth muscle homogenates. All incubations were carried out at 37 °C and in triplicate. The bars represent the means ± S.E. for >= 3 animals.

Modulation by beta -NADH of cADPR Synthesis and Metabolism-- Fig. 4A compares the rate of synthesis of cADPR from a maximally effective concentration (2.5 mM) of beta -NAD+ to the rate of synthesis of cADPR from 25 mM beta -NADH (n = 4 animals). From these data beta -NADH can be seen to be a poor substrate for ADP-ribosyl cyclase in pulmonary artery smooth muscle. However, addition of beta -NADH in combination with beta -NAD+ could produce up to a 3-fold increase in cADPR synthesis when compared with the time-matched synthesis obtained in the presence of beta -NAD+ alone. Fig. 4B shows the effect of beta -NADH (1-10 mM) on the synthesis of cADPR from a maximally effective concentration of beta -NAD+ (2.5 mM) in smooth muscle homogenates from third order branches of the pulmonary artery. beta -NADH increased the rate of synthesis of cADPR from beta -NAD+ in a concentration-dependent manner. The rate of synthesis of cADPR increased from 13.52 ± 1.5 nmol/mg of protein/h (n = 4 animals) in the absence of beta -NADH to a maximum of ~30 nmol/mg of protein/h (n = 4 animals) in the presence of 4-10 mM beta -NADH. The fact that beta -NADH increased cADPR synthesis from a maximally effective concentration of beta -NAD+ raised the possibility that beta -NADH may mediate this effect via the inhibition of cADPR hydrolase. Fig. 4C, shows that 4 mM beta -NADH inhibited the hydrolysis of cADPR (10 µM) in pulmonary artery smooth muscle homogenates. In smooth muscle homogenates of third order branches of the pulmonary artery, 3.63 ± 0.49 nmol of cADPR were metabolized/mg protein/h (n = 3 animals) in the absence of beta -NADH. This fell to 0.61 ± 0.37 nmol/mg protein/h (n = 3 animals) in the presence of 2 mM beta -NADH and was undetectable in the presence of 4 mM beta -NADH. Taken together these findings suggest that net amount of cADPR accumulated from beta -NAD+ may be increased by beta -NADH in a nonadditive and synergistic manner. This may be due, at least in part, to the inhibition by beta -NADH of cADPR hydrolase. Note that the small amount of cADPR synthesis observed with 25 mM beta -NADH may be due, in part, to the 0.5% beta -NAD+ contamination.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Regulation by beta -NADH of ADP-ribosyl cyclase and cADPR hydrolase in smooth muscle of third order branches of the pulmonary artery. A, production of cADPR from a maximally effective concentration (2.5 mM) of beta -NAD+ and from 25 mM beta -NADH in the absence of added beta -NAD+ in smooth muscle homogenates of third order branches of the pulmonary artery. B, concentration-response curve describing the effect of increasing concentrations of beta -NADH (1-10 mM) on the production of cADPR from a fixed and maximally effective concentration (2.5 mM) of beta -NAD+ in smooth muscle homogenates of third order branches of the pulmonary artery. The upper x axis shows the equivalent beta -NAD+:beta -NADH ratio. C, concentration-effect relationship for beta -NADH (0.5-4 mM) versus cADPR (10 µM) metabolism. Incubations were carried out in triplicate at 37 °C. Bars represent the means ± S.E. from >= 2 animals. **, significance of p < 0.001.

Hypoxia Increases cADPR Content in Pulmonary Artery Smooth Muscle-- We used a sea urchin egg homogenate [32P]cADPR receptor binding assay to compare the cADPR content of pulmonary artery smooth muscle under normoxic (151-160 Torr) and hypoxic (16-21 Torr) conditions. Fig. 5 shows that the level of cADPR in second order branches of the pulmonary artery increased ~2-fold in the presence of hypoxia from 1.5 ± 0.4 pmol/mg protein to 3.6 ± 0.5 pmol/mg protein (n = 3 animals). Significantly, the increase in cADPR induced by hypoxia was greater still in third order branches of the pulmonary artery, in which we measured a 10-fold increase in cADPR from 1.5 ± 0.6 pmol/mg protein to 19.7 ± 1.1 pmol/mg protein (n = 3 animals).



View larger version (5K):
[in this window]
[in a new window]
 
Fig. 5.   Elevation of cADPR content in second and third order branches of the pulmonary artery by hypoxia. Bar chart shows the total cADPR content (pmol/mg protein) in second order branches (IP) and in third order branches (RP), respectively, of the pulmonary artery under normoxic (154-160 Torr, open bars) and hypoxic (16-21 Torr, filled bars) conditions. The error bars represent the means ± S.E. of three determinations (n = 3 animals).

cADPR Releases Ca2+ from Ryanodine-sensitive SR Stores in Isolated Pulmonary Artery Smooth Muscle Cells-- We examined the sensitivity of pulmonary artery smooth muscle Ca2+ stores to cADPR. This was achieved by applying cADPR intracellularly from a patch pipette in the whole cell configuration and in current clamp mode (I = 0). Changes in intracellular Ca2+ were monitored by recording changes in the membrane potential mediated via the activation of large conductance Ca2+-activated potassium channels (BKCa) in smooth muscle cells isolated from second and third order branches of the pulmonary artery. In the absence of cADPR the membrane potential was stable at approximately -45 ± 5 mV (n = 3 cells), in agreement with the findings of others (38). In marked contrast, Fig. 6A shows the effect of intracellular dialysis of 30 µM cADPR from the patch pipette; dialysis began immediately after breaking the membrane patch under the pipette tip, i.e. at the start of the record shown. Clearly, cADPR induced a pronounced hyperpolarization of the membrane potential. The hyperpolarization reached a maximum after ~1-2 min, at which point pronounced oscillations in the membrane potential were observed. When the oscillations in membrane potential commenced the smooth muscle cells began to contract, and it proved impossible to hold the smooth muscle cells in a tight whole cell configuration for any length of time. On average (mean ± S.E.; n = 5 cells), the membrane potential hyperpolarized from -48.6 ± 5.3 mV (recorded immediately after entering the whole cell configuration) to -73 ± 2.4 mV. The hyperpolarization, oscillations in membrane potential, and cell contraction were not observed after the ryanodine-sensitive SR stores had been depleted by prior application of 10 µM ryanodine and 10 mM caffeine (Fig. 6B). Under these conditions the membrane potential remained stable at -55 ± 3 mV (n = 4 cells) for the duration of the experiment (<= 20 min). The activation of BKCa channels was confirmed by the fact that the hyperpolarization was not observed in the presence of TEA (10 mM; not shown) or iberiotoxin (100 nM; not shown). These data suggest that cADPR can induce Ca2+ release from ryanodine-sensitive SR stores in pulmonary artery smooth muscle cells.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   cADPR induces Ca2+ release from ryanodine-sensitive SR stores in isolated pulmonary artery smooth muscle cells. A, record of the effect on the membrane potential of intracellular dialysis of 30 µM cADPR from the patch pipette in a smooth muscle cell isolated from the second and third order branches of the pulmonary artery. B, effect of intracellular dialysis of 30 µM cADPR after the ryanodine-sensitive SR stores had been depleted by prior application of 10 µM ryanodine and 10 mM caffeine. The line break in A indicates where the seal between the patch pipette and the cell was broken after the pulmonary artery smooth muscle cell began to contract. Each experiment was carried out at 22 °C.

8-Bromo-cADPR Inhibits Hypoxic Pulmonary Vasoconstriction in Pulmonary Artery Rings in Vitro-- We next investigated the effect of a membrane-permeant antagonist of cADPR, 8-bromo-cADPR (25), on HPV in isolated rabbit pulmonary artery rings. Fig. 7A shows that hypoxia induced a characteristic biphasic constriction in an intact pulmonary artery ring. Fig. 7B shows the response obtained in the absence of the pulmonary artery endothelium. The initial fast transient constriction seen in Fig. 7A remains, but the second slowly developing, tonic phase of constriction is lost. Instead the constriction falls to a plateau level above base line that is maintained for the duration of exposure to hypoxia. Previous studies (11) have shown that the initial fast transient constriction and the maintained plateau rely on Ca2+ release from ryanodine-sensitive SR stores. Panels C and D of Fig. 7 show the effect on the hypoxic constriction of preincubating (10 min) intact (C) and de-endothelialized (D) arteries with 300 µM 8-bromo-cADPR. Panels E and F of Fig. 7 show the mean (1-min intervals) ± S.E. (5-min intervals) for the constriction obtained in the presence and absence of 300 µM 8-bromo-cADPR, both with (E) and without (F) the endothelium. The peak of the fast transient constriction remained unaffected in the presence of 300 µM 8-bromo-cADPR (n = 6 arteries). In marked contrast, the second phase of the hypoxia-induced constriction was abolished both in the presence and absence of the endothelium (n = 6 arteries). These data suggest that prolonged, cADPR-dependent SR Ca2+ release is required to maintain hypoxia-induced constriction of pulmonary artery smooth muscle. However, the full development of phase 2 of HPV also requires the release of an endothelium-derived vasoconstrictor (10). Because 8-bromo-cADPR abolished phase 2 of HPV when the endothelium was present, we cannot rule out that this was due, in part, to its inhibition of vasoconstrictor release from the endothelium or the blockade of the action of the vasoconstrictor in the smooth muscle. We know that the endothelium-derived vasoconstrictor induces constriction by sensitizing the smooth muscle myofilaments to Ca2+ and that it does not appear to mobilize Ca2+ in its own right (10). Thus, we would expect arteries that have been preconstricted by Ca2+ derived from another source (e.g. the extracellular fluid) to constrict further on release of the endothelium-derived vasoconstrictor during hypoxia, even when maintained SR Ca2+ release has been blocked by 8-bromo-cADPR. Because K+ induces pulmonary artery constriction by depolarizing the smooth muscle cell membrane and activating voltage-gated Ca2+ channels, we were able to preconstrict pulmonary arteries with K+ even in the presence of 8-bromo-cADPR. We used 20 mM K+ to provide a plateau constriction similar in magnitude (2.4 ± 0.2 mN/mm, n = 6) to the endothelium-independent constriction that was maintained by hypoxia and blocked by 8-bromo-cADPR (2.8 ± 1.1 mN/mm, n = 6; see also Fig. 7 D). Fig. 8A shows a control response to hypoxia (16-21 Torr) as before. Fig. 8B shows the response of the same vessel to hypoxia after the vessel had been preconstricted with 20 mM K+. Fig. 8C shows the effect of 300 µM 8-bromo-cADPR on the constriction to hypoxia, after the vessel had been preconstricted with 20 mM K+. Under these conditions and when reported as a percentage of the constriction to 75 mM K+, hypoxia induced a typical biphasic constriction similar in magnitude to control both in the presence and absence of 8-bromo-cADPR. The peak of phase 1 measured 62 ± 11% in the absence of 8-bromo-cADPR and in the absence of K+ (20 mM)-induced preconstriction; 55 ± 10% in the absence of 8-bromo-cADPR and in the presence of K+ (20 mM)-induced preconstriction; and 53 ± 7% in the presence of 300 µM 8-bromo-cADPR and K+ (20 mM)-induced preconstriction (n = 5 arteries). The peak of phase 2 of HPV after 40 min of exposure to hypoxia measured 32 ± 8% in the absence of 8-bromo-cADPR and in the absence of K+ (20 mM)-induced preconstriction; 36 ± 8% in the absence of 8-bromo-cADPR and in the presence of K+ (20 mM)-induced preconstriction; and 25 ± 9% in the presence of both 300 µM 8-bromo-cADPR and K+ (20 mM)-induced preconstriction (n = 5 arteries). This finding suggests that although 8-bromo-cADPR inhibits SR Ca2+ release to hypoxia, it does not affect hypoxia-induced release of the endothelium-derived vasoconstrictor(s), subsequent myofilament sensitization, or the constriction to Ca2+ per se.



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 7.   Hypoxic pulmonary vasoconstriction is inhibited by 8-bromo-cADPR in the presence and absence of the pulmonary artery endothelium. A, control constriction to 75 mM K+. The pulmonary artery ring was then exposed to hypoxia (16-21 Torr) for 30 min. After the artery had recovered from the exposure to hypoxia, the vessel was then exposed once more to 75 mM K+. B, first shows a control response of a de-endothelialized pulmonary artery ring to 75 mM K+ and then the effect of exposing the vessel to hypoxia (16-21 Torr). C, control response to K+ (75 mM) and then the effect of preincubation (10 min) with 300 µM 8-bromo-cADPR on the hypoxia (16-21 Torr)-induced constriction of a pulmonary artery ring in the presence of the endothelium. D, control response to K+ (75 mM) and then the effect of preincubation (10 min) with 300 µM 8-bromo-cADPR on the hypoxia (16-21 Torr)-induced constriction of a pulmonary artery ring in the absence of the endothelium. The records in A and C and those in B and D, respectively, were obtained from the same artery at 37 °C. E and F, means (1-min intervals) ± S.E. (5-min intervals) for six experiments carried out in the presence (E) and absence (F) of the endothelium. The closed and open circles represent the constriction measured in the absence and presence of 300 µM 8-bromo-cADPR, respectively.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   Hypoxic pulmonary vasoconstriction is not inhibited by 8-bromo-cADPR in pulmonary arteries preconstricted with potassium. A, control constriction to 75 mM K+. The pulmonary artery ring was then exposed to hypoxia (16-21 Torr) for 30 min. After the artery had recovered from the exposure to hypoxia, the vessel was then exposed once more to 75 mM K+. B, first shows a control response to 75 mM K+. The vessel was then preconstricted with 20 mM K+ and subsequently exposed to hypoxia (16-21 Torr). C, shows a control response to K+ (75 mM). The vessel was then preincubated (10 min) with 300 µM 8-bromo-cADPR, preconstricted with 20 mM K+ and subsequently exposed to hypoxia (16-21 Torr). The results were obtained from the same artery at 37 °C.

Extracellular application of 300 µM cADPR, which is membrane-impermeant, had no effect on either resting tone (after 60 min) or acute HPV (20 min of preincubation) in isolated pulmonary artery rings (n = 4; not shown). This supports the view that the cADPR antagonist 8-bromo-cADPR is acting intracellularly.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have investigated the possible role of ADP-ribosyl cyclase, cADPR hydrolase, and cADPR as a redox sensor in pulmonary artery smooth muscle. Our findings suggest that increased cADPR synthesis may mediate, in part, the hypoxia-induced increase in SR Ca2+ release in pulmonary artery smooth muscle and hence contribute to HPV.

We measured a high level of cADPR production in smooth muscle homogenates from pulmonary arteries, whereas little synthesis could be detected in smooth muscle homogenates from aortic or mesenteric arteries. A similar trend was observed with respect to the metabolism of cADPR, although a small amount of metabolism was observed in homogenates of both aortic and mesenteric artery smooth muscle. Furthermore we have shown that synthesis and metabolism of cADPR occurs intracellularly. These findings point to an important role for ADP-ribosyl cyclase, cADPR hydrolase and cADPR in the regulation of pulmonary artery function. Support for this proposal comes from the fact that the level of cADPR synthesis in pulmonary artery homogenates was inversely related to artery diameter, being 18-fold higher in homogenates from the small third order branches than it was in the homogenates of the main extrapulmonary artery. Because the magnitude of the hypoxic constriction is also inversely related to artery diameter (39, 40), the ability of hypoxia to constrict pulmonary arteries increases with the increasing levels of smooth muscle ADP-ribosyl cyclase and cADPR hydrolase activity. An intriguing possibility, therefore, is that hypoxia may increase the rate of synthesis of cADPR in pulmonary artery smooth muscle.

In a separate series of experiments, we found that beta -NADH induced a concentration-dependent increase in the rate of cADPR synthesis from a fixed and maximally effective concentration of its substrate beta -NAD+. Because beta -NADH was found to be a poor substrate for cADPR synthesis, this effect was clearly nonadditive, i.e. synergistic. We also found beta -NADH to inhibit, in a concentration-dependent manner, cADPR metabolism in pulmonary artery smooth muscle homogenates. Thus, beta -NADH may promote an increase in cADPR accumulation from beta -NAD+, at least in part, by blocking the metabolism of cADPR by a cADPR hydrolase. The effect of beta -NADH on cADPR synthesis may be of importance to the regulation of O2-sensing cells because the redox state of such cells is uniquely sensitive to changes in O2 (3, 20, 21, 22), and hypoxia has been shown to increase beta -NADH levels in all O2-sensing cells studied to date (3, 20, 21, 22, 23). Previous investigations of pulmonary artery smooth muscle suggest that total tissue beta -NAD+ levels may be in the mM range during normoxia and hypoxia and that during hypoxia a small fall in beta -NAD+ levels yields a large increase in beta -NADH levels. Estimates suggest that beta -NADH concentration in the smooth muscle may increase at least 5-fold during hypoxia from ~0.03 mM (normoxia; Ref. 23) to 0.15 mM (hypoxia; Ref. 23). However, it should be noted that any estimates of total tissue beta -NAD+ and beta -NADH levels are likely underestimates of the true levels that may be experienced in intact cells. The estimates given here assume a total tissue H2O content of 0.75 liter/Kg and assume that the extracellular fluid would account for 20% of the total tissue H2O. They do not take into account known subcellular compartmentalization, which may result in significant concentration of beta -NAD+ and beta -NADH levels and, indeed, cADPR. In fact beta -NAD+/beta -NADH and the enzymes for cADPR synthesis and metabolism may be localized in cellular compartments from the plasma membrane to the mitochondria (41). In addition hypoxia may reduce the redox state of the cytoplasmic compartment, by modulating glycolysis (42) and/or the mitochondrial redox state (20). It is, however, clear that these data give equivalent beta -NAD+:beta -NADH ratios of ~17 and 5 (23), respectively, and the latter is close to the range (5-0.7) of beta -NAD+:beta -NADH ratios, over which our data indicate that we may see an increase in cADPR synthesis from beta -NAD+ (Fig. 4B).

Given the above findings and the fact that the hypoxia-induced increase in NAD(P)H autofluorescence in carotid body type I cells occurs over the same time scale as does the hypoxia-induced increase in intracellular Ca2+ concentration (21), it seemed likely that hypoxia may promote SR Ca2+ release by reducing the NAD(P):NAD(P)H ratio and by subsequently increasing cADPR synthesis. This proposal gained support from the finding that tissue cADPR levels increased when pulmonary arteries were exposed to hypoxia under physiological conditions. Furthermore, a 5-fold greater increase in cADPR content was observed in third order branches than in second order branches of the pulmonary artery. Thus, like the enzyme activities (see above), the magnitude of the hypoxia-induced increase in cADPR content was inversely related to artery diameter, as is the sensitivity of the arteries to hypoxia (39, 40).

In functional studies we first showed that cADPR induced Ca2+ release from ryanodine-sensitive SR stores in isolated pulmonary artery smooth muscle cells, as does hypoxia (11, 12, 13). We therefore investigated the role of cADPR in HPV, using a membrane-permeant cADPR antagonist, 8-bromo-cADPR. Our findings strongly suggest that hypoxia activates both cADPR-dependent and cADPR-independent Ca2+ release from ryanodine-sensitive SR stores. The first transient phase of constriction to hypoxia remained unaffected in the presence of 8-bromo-cADPR. Thus, a cADPR-independent O2-sensing mechanism must initiate the ryanodine-sensitive SR Ca2+ release associated with this phase of HPV (11). Recent investigations have suggested that phase 1 of HPV may result from an initial fall in ATP levels and inhibition of the SR Ca2+ ATPase, leading to an increase in the net efflux of Ca2+ from the SR (Ref. 43 and Fig. 9). This may in turn promote calcium influx because of the subsequent activation of the store refilling current (43). These findings (43) and our own (11), do not support the view (2-8) that phase 1 of HPV in isolated vessels is mediated by Ca2+influx through voltage-gated Ca2+ channels. In marked contrast, the subsequent sustained phase of acute HPV in de-endothelialized pulmonary artery rings (Fig. 7B), which is also mediated by ryanodine-sensitive SR Ca2+ release (11), was blocked by 8-bromo-cADPR. This finding suggests that a sustained increase in SR Ca2+ release and hence constriction may depend on an increase in cADPR synthesis during HPV (Fig. 9). Perhaps the most important observation, however, was that the second tonic phase of HPV in intact isolated pulmonary artery rings was abolished by 8-bromo-cADPR and could be reconstituted if the arteries were preconstricted with K+ (Figs. 7 and 8). These findings suggest that an increase in cADPR levels and subsequent SR Ca2+ release in the smooth muscle is essential for the maintenance of acute HPV. Furthermore they show that 8-bromo-cADPR did not block (a) constriction to Ca2+ per se, (b) the release of the endothelium-derived vasoconstrictor in response to hypoxia, or (c) the increase in myofilament Ca2+ sensitivitiy promoted by the released vasoconstrictor. Thus, the release of the endothelium-derived vasoconstrictor during the second tonic phase of HPV (9, 10, 40) may be insufficient to promote pulmonary artery constriction in the absence of maintained cADPR-dependent SR Ca2+ release, despite the fact that the vasoconstrictor may activate a Rho associated kinase and increase smooth muscle myofilament Ca2+ sensitivity (Ref. 44 and Fig. 9).



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 9.   Schematic representation of the proposed redox sensing pathway. We propose that hypoxia may increase beta -NADH levels and thereby increase the net amount of cADPR accumulated from beta -NAD+, at least in part, by inhibiting cADPR metabolism by the cADPR hydrolase (CH). The increase in cADPR synthesis in combination with the inhibition of the SR Ca2+ ATPase by hypoxia may then promote SR Ca2+ release from ryanodine-sensitive SR stores and constriction via Ca2+-dependent activation myosin light chain kinase (MLCK). The release by hypoxia of a vasoconstrictor from the pulmonary artery endothelium may then promote further constriction by activating a Rho-associated kinase (ROCK), leading to the inhibition of smooth muscle myosin phosphatase (SMMP) and an increase in myofilament Ca2+ sensitivity. AC, ADP-ribosyl cyclase; ADPR, ADP-ribose.

Given the above, it may be of some significance that the level of cADPR synthesis is at least 2 orders of magnitude higher in pulmonary artery smooth muscle than it is in systemic artery smooth muscle. Thus, in pulmonary artery smooth muscle hypoxia may induce an increase in cADPR levels at least 2 orders of magnitude greater than that observed in systemic artery smooth muscle. This may provide a platform for the evident pulmonary selective effects of hypoxia; systemic arteries dilate in response to hypoxia. This is a significant point, because all three ryanodine receptor subtypes (RyR1, RyR2, and RyR3) may be present in both systemic and pulmonary vascular smooth muscle (45), and all three RyR subtypes can be expressed in a cADPR-sensitive form (46-48).

In summary, our findings suggest that (a) the enzyme activities for the metabolism of cADPR are significantly higher in pulmonary artery smooth muscle than they are in systemic artery smooth muscle; (b) the expression of these enzyme activities was highest in the smaller pulmonary arteries, which exhibit the highest sensitivity to hypoxia; (c) an increase in beta -NADH concentration increased the net amount of cADPR synthesized from beta -NAD+, and this was due, at least in part, to the inhibition by beta -NADH of cADPR metabolism; (d) hypoxia increased cADPR levels in pulmonary arteries; (e) cADPR induced Ca2+ release from ryanodine-sensitive SR stores in pulmonary artery smooth muscle cells; and (f) 8-bromo-cADPR, a cADPR antagonist, abolished the sustained phase of acute HPV in intact arteries. We propose that ADP-ribosyl cyclase, cADPR hydrolase, and cADPR act as a redox sensor that couples changes in the cellular redox potential to SR Ca2+ release (Fig. 9) and that cADPR is the primary mediator of acute HPV. This pathway may offer an important new therapeutic target for the treatment of hypoxic pulmonary hypertension. It is also possible that this pathway may play a role in (a) ischemia/ischemic reperfusion injury and (b) Ca2+ signaling in pancreatic beta  cells, in which cADPR may regulate stimulus secretion coupling and in which glucose induces concomitant oscillations in NAD(P)H autofluorescence and in cytoplasmic Ca2+ (34, 49, 50).


    ACKNOWLEDGEMENT

We are grateful to Dr. Grant Churchill for helpful discussion.


    FOOTNOTES

* This work was supported by the Wellcome Trust and the BBSRC.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of a Special Biotechnology and Biological Sciences Research Council studentship. Present address: Inst. of Molecular Physiology, Sheffield University, Alfred Denny Bldg., Western Bank, Sheffield, S10 2TN, UK.

** Wellcome Trust Non-Clinical Lecturer. To whom correspondence should be addressed: Division of Biomedical Sciences, School of Biology, Buke Building, University of St. Andrew, St. Andrew, Fife, KY 169TS, UK. Tel: 44-1-334-463579; Fax: 44-1334-463600; E-mail: ame3@st-and.ac.uk.

|| Wellcome Trust Senior Research Fellow.

Published, JBC Papers in Press, December 14, 2000, DOI 10.1074/jbc.M004849200


    ABBREVIATIONS

The abbreviations used are: HPV, hypoxic pulmonary vasoconstriction; SR, sarcoplasmic reticulum; cADPR, cyclic ADP-ribose; RyR, ryanodine receptor.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Von Euler, U. S., and Liljestrand, G. (1946) Acta Physiol. Scand. 12, 301-320
2. Post, J., Hume, J., Archer, S., and Weir, E. (1992) Am. J. Physiol. 262, C882-C890[Abstract/Free Full Text]
3. Archer, S. L., Huang, J., Henry, T., Peterson, D., and Weir, E. K. (1993) Circ. Res. 73, 1100-1112[Abstract]
4. Osipenko, O. N., Evans, A. M., and Gurney, A. M. (1997) Br. J. Pharmacol. 120, 1461-1470[Abstract]
5. Harder, D., Madden, J., and Dawson, C. (1985) J. Appl. Physiol. 59, 1389-1393[Abstract/Free Full Text]
6. Madden, J., Vadula, M., and Kurup, V. (1992) Am. J. Physiol. 263, L384-L393[Abstract/Free Full Text]
7. Cornfield, D., Stevens, T., McMurty, I., Abman, S., and Rodman, D. (1993) Am. J. Physiol. 265, L1-L4[Abstract/Free Full Text]
8. Salvaterra, C., and Goldman, W. (1993) Am. J. Physiol. 264, L323-L328[Abstract/Free Full Text]
9. Kovitz, K. L., Aleskowitch, J. T., Sylvester, J. T., and Flavahan, N. A. (1993) Am. J. Physiol. 260, L516-L521
10. Robertson, T. P., Aaronson, P. I., and Ward, J. P. T. (1995) Am. J. Physiol. 268, H301-H307[Abstract/Free Full Text]
11. Dipp, M., Nye, P. C. G., and Evans, A. M. (2000) J. Physiol. 526, S26P
12. Jabr, R. I., Toland, H., Gelband, C. H., Wang, X. X., and Hume, J. R. (1997) Br. J. Pharmacol. 122, 21-30[Abstract]
13. Gelband, C. H., and Gelband, H. (1997) Circulation 96, 3647-3654[Abstract/Free Full Text]
14. Lee, H. C., Walseth, T. F., Bratt, G. T., Hayes, R. N., and Clapper, D. L. (1989) J. Biol. Chem. 264, 1608-1615[Abstract/Free Full Text]
15. Walseth, T., Aarhus, R., Zeleznikar, R., and Lee, H. C. (1991) Biochim. Biophys. Acta 1094, 113-120[Medline] [Order article via Infotrieve]
16. Galione, A. (1993) Science 259, 325-326[Medline] [Order article via Infotrieve]
17. Galione, A., Lee, H. C., and Busa, W. B. (1991) Science 253, 1143-1146[Medline] [Order article via Infotrieve]
18. Galione, A., and Summerhill, R. S. (1996) in Ryanodine Receptors (Sorrentino, V., ed) , pp. 52-70, CRC Press, Boca Raton, FL
19. Lee, H. C. (1997) Physiol. Rev. 77, 1133-1164[Abstract/Free Full Text]
20. Duchen, M. R. (1999) J. Physiol. 516, 1-17[Abstract/Free Full Text]
21. Biscoe, T. J., and Duchen, M. R. (1990) J. Physiol. 428, 39-59[Abstract]
22. Youngsson, C., Nurse, C., Yeger, H., and Katz, E. (1993) Nature 356, 153-155
23. Shigemori, K., Ishizaki, T., Matsukawa, S., Sakai, A., Nakai, T., and Miyabo, S. (1996) Am. J. Physiol. 270, L803-L809[Abstract/Free Full Text]
24. Clapp, L. H., and Gurney, A. M. (1991) Exp. Physiol. 76, 677-693[Abstract]
25. Sethi, J. K., Empson, R. M., Bailey, V. C., Potter, B. V., and Galione, A. (1997) J. Biol. Chem. 272, 16358-16363[Abstract/Free Full Text]
26. Sethi, J. K., Empson, R. M., and Galione, A. (1997) Biochem. J. 319, 613-617
27. Clapper, D. L., Walseth, T. F., Dargie, P. J., and Lee, H. C. (1987) J. Biol. Chem. 262, 9561-9568[Abstract/Free Full Text]
28. Wilson, H. L., and Galione, A. (1998) Biochemical J. 331, 837-843[Medline] [Order article via Infotrieve]
29. Graeff, R. M., Walseth, T. F., Fryxell, K., Branton, W. D., and Lee, H. C. (1994) J. Biol. Chem. 269, 30260-30267[Abstract/Free Full Text]
30. Evans, W. H. (1986) in Biological Membranes (Evans, W. H., ed) , pp. 1-35, IRL Press, Oxford
31. Evans, A. M., Osipenko, O. N., and Gurney, A. M. (1996) J. Physiol. 496.2, 407-420[Abstract]
32. Halpern, W., and Mulvany, M. J. (1987) J. Physiol. 265, 21P-23P
33. Lee, H. C. (1991) J. Biol. Chem. 266, 2276-2281[Abstract/Free Full Text]
34. Okamoto, H., Takasawa, S., and Nata, K. (1997) Diabetologica 40, 1485-1491[CrossRef][Medline] [Order article via Infotrieve]
35. Galione, A., Cancela, J-M., Churchill, G. C., Genazzani, A. A., Lad, C., Thomas, J., Wilson, H., and Terrar, D. A. (2000) in Methods in Calcium Signalling (Putney, J. W., Jr., ed) , pp. 249-296, CRC Press, Boca Raton, FL
36. Graeff, R. M., Walseth, T. F., and Lee, H. C. (1997) Methods Enzymol. 280, 230-241[Medline] [Order article via Infotrieve]
37. Howard, H. M., Grimaldi, J. C., Bazan, J. F., Lund, F. E., Santos-Argumedo, L., Parkhouse, R. M. E., Walseth, T. F., and Lee, H. C. (1993) Science 262, 1056-1059[Medline] [Order article via Infotrieve]
38. Bae, Y. M., Park, M. K., Lee, S. H., Ho, W. K., and Earm, Y. E. (1999) J. Physiol. 514.2, 747-758[Abstract/Free Full Text]
39. Wadsworth, R. M. (1994) Trends. Pharmacol. Sci. 15, 47-53[CrossRef][Medline] [Order article via Infotrieve]
40. Leach, R. M., Robertson, T. P., Twort, C. H. C., and Ward, J. P. T. (1994) Am. J. Physiol. 266, L223-L231[Abstract/Free Full Text]
41. Zeigler, M. (2000) Eur. J. Biochem. 267, 1550-1564[Abstract/Free Full Text]
42. Leach, R. M., Sheehan, D. W., Chacko, V. P., and Sylvester, J. T. (2000) Am. J. Physiol. 278, L294-L304
43. Robertson, T. P., Hague, D., Aaronson, P. I., and Ward, J. P. T. (2000) J. Physiol. 525, 669-680[Abstract/Free Full Text]
44. Robertson, TT. P., Dipp, M., Ward, J. P. T., Aaronson, P. I., and Evans, A. M. (2000) Br. J. Pharmacol. 131, 5-9[Abstract/Free Full Text]
45. Hermann-Frank, A., Darling, E., and Meissner, G. (1991) Pflügers Arch. Eur. J. Physiol 418, 353-359[Medline] [Order article via Infotrieve]
46. Yamaguchi, N., and Kasai, M. (1997) Biochem. Biophys. Res. Commun. 240, 772-777[CrossRef][Medline] [Order article via Infotrieve]
47. Cui, Y., Galione, A., and Terrar, D. A. (1999) Biochem. J. 342, 269-273[CrossRef][Medline] [Order article via Infotrieve]
48. Sonnleitner, A., Conti, A., Bertocchini, F., Schindler, H., and Sorrentino, V. (1998) EMBO J. 17, 2790-2798[Abstract/Free Full Text]
49. Maechler, P., Kennedy, E. D., Pozzan, T., and Wollheim, C. B. (1997) EMBO J. 16, 3833-3841[Abstract/Free Full Text]
50. Salgado, A. P., Pereira, F. C., Seica, R. M., Fernandes, A. P., Flatt, P. R., Santos, R. M., Rosario, L. M., and Ramasamy, R. (1999) Mol. Cell. Endocrinol. 154, 79-88[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.